Sign in to continue:

Tuesday, March 10th, 2026

Besunyen Holdings Announces Board Meeting to Approve 2025 Final Results and Dividend on 20 March 2026 1

Besunyen Holdings Company Limited (Stock Code: 926), a leading health and wellness company incorporated in the Cayman Islands and listed on the Hong Kong Stock Exchange, has announced the date of its upcoming board meeting. This development is of significant interest to investors and shareholders due to its potential impact on share value and dividend expectations.

Key Highlights from the Announcement

  • Board Meeting Scheduled: The Board of Directors will convene on Friday, 20 March 2026.
  • Purpose of Meeting: The meeting will focus on:
    • Reviewing and approving the final results of the Company and its subsidiaries for the financial year ended 31 December 2025.
    • Considering a recommendation for the declaration and payment of a final dividend, if any.
  • Potential Share Price Impact: Both the release of annual results and any announcement regarding dividends are traditionally viewed as price-sensitive information that could influence the company’s share price.

Details for Shareholders

  • The upcoming results announcement will provide detailed insight into Besunyen Holdings’ financial performance for 2025, allowing investors to assess the company’s growth trajectory, profitability, and potential return on investment.
  • The Board’s consideration of a final dividend is particularly noteworthy. A dividend declaration, or changes in dividend policy, can have a direct impact on the stock’s attractiveness to income-focused investors.
  • Shareholders should be alert to the outcome of this meeting, as the decisions made could result in significant share price movements, either positively (if results and dividends exceed expectations) or negatively (if results disappoint or no dividend is declared).

Company Leadership

The current Board includes experienced executives and independent directors:

  • Executive Directors:
    • Mr. Zhao Yihong (Chairman and Chief Strategy Officer)
    • Ms. Gao Yan (Vice Chairman)
    • Mr. Feng Bing (Chief Executive Officer)
    • Mr. Yu Hongjiang (Executive Vice President, Chief Operating Officer, and Chief Financial Officer)
  • Independent Non-Executive Directors:
    • Mr. He Yuanping
    • Mr. Shi Xiangxin
    • Dr. Chen Yang

What Investors Should Watch For

  • The final results for 2025, which will be made public after the board meeting, could provide new guidance about the company’s prospects and financial health.
  • Dividend decisions are critical for market sentiment; an increase, decrease, or omission of the final dividend could all trigger market reaction.
  • Given the regulatory significance and the potential impact on the stock price, investors are advised to monitor the company’s official announcements closely around the date of the meeting.

Disclaimer: This article is prepared for informational purposes only and does not constitute investment advice. Investors are urged to conduct their own due diligence and consult their financial advisors before making any investment decisions. The information provided herein is based on a company announcement and is subject to change.

View BESUNYEN Historical chart here



Wanjia Group Holdings Limited Rights Issue 2026: Full Details, Timetable, Subscription Price & Shareholder Information

Wanjia Group Holdings Announces Major Rights Issue: Key Details for Investors Wanjia Group Holdings Limited Announces 1-for-1 Rights Issue: Key Details for Investors Wanjia Group Holdings Limited (Stock Code: 401) has released a detailed...

BeOne Medicines Ltd. 2025 Swiss Redomiciliation, Financial Statements, Audit Reports, and Global Business Update

BeOne Medicines Ltd. 2025 Financial Report – Key Highlights for Investors BeOne Medicines Ltd. Releases Detailed 2025 Financial Statements and Business Update Overview BeOne Medicines Ltd. (formerly BeiGene, Ltd.), a global pharmaceutical company now...

Natural Beauty Bio-Technology 2025 ESG Report: Sustainable Development, Climate Action, Corporate Governance & Innovation

Natural Beauty Bio-Technology 2025 ESG Report: Investor Key Highlights Natural Beauty Bio-Technology Limited 2025 ESG Report: Key Investor Highlights Overview Natural Beauty Bio-Technology Limited (“Natural Beauty” or “the Group”) has released its 2025 Environmental,...

   Ad